

## Short Communication

# Diabetes prevalence is associated with serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in US middle-aged Caucasian men and women: a cross-sectional analysis within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Kaye E. Brock<sup>1\*</sup>, Wen-Yi Huang<sup>2</sup>, David R. Fraser<sup>3</sup>, Liang Ke<sup>1,4</sup>, Marilyn Tseng<sup>5</sup>, Rebecca S. Mason<sup>6</sup>, Rachael Z. Stolzenberg-Solomon<sup>2</sup>, D. Michal Freedman<sup>2</sup>, Jiyoun Ahn<sup>7</sup>, Ulrike Peters<sup>8</sup>, Catherine McCarty<sup>9</sup>, Bruce W. Hollis<sup>10</sup>, Regina G. Ziegler<sup>2</sup>, Mark P. Purdue<sup>2</sup> and Barry I. Graubard<sup>2</sup>

<sup>1</sup>Faculty of Health Sciences, University of Sydney, Lidcombe, NSW, Australia

<sup>2</sup>Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

<sup>3</sup>Faculty of Veterinary Sciences, University of Sydney, Camperdown, NSW, Australia

<sup>4</sup>Department of Research and Development, George Institute, Beijing, People's Republic of China

<sup>5</sup>Department of Kinesiology, California Polytechnic State University, San Luis Obispo, CA, USA

<sup>6</sup>Bosch Institute, Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia

<sup>7</sup>Division of Epidemiology, Department of Environmental Medicine, NYU School of Medicine, NY, USA

<sup>8</sup>Fred Hutchinson Cancer Research Center in Seattle, Seattle, WA, USA

<sup>9</sup>Marshfield Clinic Research Foundation, Marshfield, WI, USA

<sup>10</sup>Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA

(Received 16 June 2010 – Revised 13 January 2011 – Accepted 14 February 2011 – First published online 17 May 2011)

### Abstract

Hypovitaminosis D may be associated with diabetes, hypertension and CHD. However, because studies examining the associations of all three chronic conditions with circulating 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) are limited, we examined these associations in the US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial (*n* 2465). Caucasian PLCO participants selected as controls in previous nested case–control studies of 25(OH)D and 1,25(OH)<sub>2</sub>D were included in this analysis. Diabetes, CHD and hypertension prevalence, risk factors for these conditions and intake of vitamin D and Ca were collected from a baseline questionnaire. Results indicated that serum levels of 25(OH)D were low (<50 nmol/l) in 29% and very low (<37 nmol/l) in 11% of subjects. The prevalence of diabetes, hypertension and CHD was 7, 30 and 10%, respectively. After adjustment for confounding by sex, geographical location, educational level, smoking history, BMI, physical activity, total dietary energy and vitamin D and Ca intake, only diabetes was significantly associated with lower 25(OH)D and 1,25(OH)<sub>2</sub>D levels. Caucasians who had 25(OH)D ≥80 nmol/l were half as likely to have diabetes (OR 0.5 (95% CI 0.3, 0.9)) compared with those who had 25(OH)D <37 nmol/l. Those in the highest quartile of 1,25(OH)<sub>2</sub>D (≥103 pmol/l) were less than half as likely to have diabetes (OR 0.3 (95% CI 0.1, 0.7)) than those in the lowest quartile (<72 pmol/l). In conclusion, the independent associations of 25(OH)D and 1,25(OH)<sub>2</sub>D with diabetes prevalence in a large population are new findings, and thus warrant confirmation in larger, prospective studies.

**Key words:** Diabetes; Vitamin D status; 25-Hydroxyvitamin D; 1,25-Dihydroxyvitamin D

**Abbreviations:** 1,25(OH)<sub>2</sub>D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; PA, physical activity.

\* **Corresponding author:** K. E. Brock, fax +61 2 93519540, email kaye.brock@sydney.edu.au

Vitamin D is a steroid pro-hormone synthesised in the skin following UV exposure or through supplemental or dietary intake. In addition to maintaining bone and muscle health, vitamin D has recently been postulated to protect against immune dysfunction, cancer<sup>(1)</sup>, cardiovascular conditions<sup>(2,3)</sup>, hypertension<sup>(3,4)</sup>, metabolic syndrome and diabetes<sup>(5)</sup>.

The concentration of 25-hydroxyvitamin D (25(OH)D), the major circulating form of vitamin D in the blood, rises and falls with the supply of vitamin D; on the other hand, the concentration of circulating 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) (the biologically active form) is thought to be kept under tight homeostatic control and is thus largely independent of vitamin D supply, except in severe deficiency<sup>(1)</sup>.

As early as the 1980s, animal studies identified the expression of the vitamin D receptor in rat pancreatic cells and demonstrated that vitamin D deficiency inhibits the production of insulin<sup>(6,7)</sup>. To our knowledge, no large epidemiological analysis study has investigated simultaneously diabetes, hypertension and CHD risk together with vitamin D blood levels. Thus, the aim of the present study was to investigate the association between diabetes, hypertension and CHD and two serum bio-markers associated with vitamin D function, 25(OH)D and 1,25(OH)<sub>2</sub>D.

## Materials and methods

In the present study, we analysed data from subjects selected as controls in five previous case–control studies of circulating vitamin D biomarkers (25(OH)D and 1,25(OH)<sub>2</sub>D) nested within the Prostate Lung Colon and Ovarian Trial (PLCO), which was a large, randomised, controlled multicentre trial in the USA with 155 000 men and women at sites in Birmingham, AL; Denver, CO; Detroit, MI; Honolulu, HI; Marshfield, WI; Minneapolis, MN; Pittsburgh, PA; Salt Lake City, UT; St Louis, MO; and Washington, DC, which was designed to evaluate selected methods for the early detection of these four cancers as well as non-Hodgkin's lymphoma, breast and pancreatic cancer. Enrolment began on 1 November 1993 and ended on 30 June 2001<sup>(8)</sup>. Details of these studies of colorectal adenoma, non-Hodgkin's lymphoma and prostate, breast and pancreatic cancer are described elsewhere<sup>(9)</sup>. Briefly, we included 399 controls used for a study of colorectal adenoma (matched to cases by sex and race), 286 controls used for a study of non-Hodgkin's lymphoma, 713 controls used for a study of prostate cancer (matched to cases by age, time since screening and year of follow-up), 932 controls used for a study of breast cancer (matched to cases by age and year of blood draw) and 350 used for a study of pancreatic cancer (matched to cases by age, sex, race and date of blood draw). Of these controls, 59 were included in more than one study; thus, in total, 2621 control subjects from the Prostate Lung Colon and Ovarian Trial were included in this present data analysis. As there were only 157 non-Caucasians in these data, we only present results for these Caucasian subjects (25(OH)D, *n* 2465; 1,25(OH)<sub>2</sub>D, *n* 1369). At the initial screening, all participants were asked to complete a questionnaire on medical history, including diabetes, hypertension and CHD as well as demography, anthropometry, lifestyle factors

(including smoking history, menopausal hormone therapy use and vigorous physical activity (PA) during the previous year) and usual dietary intake over the 12 months before enrolment (137-item FFQ and fourteen questions about intake of vitamin and mineral supplements)<sup>(10)</sup>. Because of the self-reported nature of the questionnaire, the medical diagnosis questions were repeated on the same population 5 years later with 87% repeatability for diabetes, 89% for hypertension and only 55% for CHD. Daily nutrient intake from foods was calculated by multiplying the reported frequency of consumption of each food item by the nutrient composition of the imputed sex-specific portion size, using the nutrient database from the US Department of Agriculture<sup>(11)</sup>. Ca and vitamin D intakes were measured both from food and supplemental sources. Serum samples were collected during the baseline visit and stored at  $-70^{\circ}\text{C}$ . Levels of serum 25(OH)D and 1,25(OH)<sub>2</sub>D for subjects were determined at baseline using a radio-iodinated tracer assay in the laboratories of Horst and Hollis<sup>(12,13)</sup>. Replicate blinded quality-control samples from two to four different individuals were included in all 25(OH)D and 1,25(OH)<sub>2</sub>D batches. The overall CV for 25(OH)D were 16.3% for the colorectal adenoma, 11.4% for non-Hodgkin's lymphoma, 5.9% for prostate, 8.2% for the breast study and 4.7% for the pancreas study and for 1,25(OH)<sub>2</sub>D were 16.3 and 12.8% for adenoma and breast studies, respectively.

Dummy variables coded to represent each of the centres in the study and each of the control series (from the five case–control studies) were included as covariates in all models as well as age, smoking, educational status, BMI, total dietary energy and PA, as they are known risk factors for diabetes, hypertension and CHD in previous studies. All these variables were included as *a priori* confounders/covariates in all multivariable regression models. Unconditional logistic regression analyses were conducted with diabetes, hypertension and CHD as health outcomes, with 25(OH)D nmol/l (categorised as  $>80$ , 50–80, 37–50 and  $<37$ ) as either the independent variable for vitamin D status or 1,25(OH)<sub>2</sub>D pmol/l (in quartiles:  $\geq 103$ ,  $\geq 86$ –103,  $\geq 72$ –86 and  $<72$ ). Vitamin D and Ca intakes (diet plus supplements) were also calculated as potential independent variables and also included in all models.

Linear trends of ordered categorical variables (e.g. categories of 25(OH)D, 1,25(OH)<sub>2</sub>D, BMI and vitamin D and Ca intake) were assessed using continuous values for each variable and applying a likelihood ratio test<sup>(14)</sup>. All statistical analyses were performed using the SPSS 15 statistical package (SPSS, Inc., Chicago, IL, USA). All *P* values are two-sided.

## Results

The characteristics of the study participants are reported in Table 1. Serum 25(OH)D levels varied seasonally, with the highest levels during the summer and autumn months and the lowest levels during winter and spring (unlike 1,25(OH)<sub>2</sub>D levels). Unadjusted 25(OH)D and 1,25(OH)<sub>2</sub>D values were significantly lower for diabetics (Fig. 1(a) and (b)), those with hypertension and those with CHD (data not shown). Apart from sunshine exposure, other independent

predictors of 25(OH)D levels in these data have been previously reported to be high dietary and supplement intake of vitamin D and Ca and menopausal hormone therapy use in women, as well as having a high BMI and low PA levels<sup>(9)</sup>. As 1,25(OH)<sub>2</sub>D levels are under tight metabolic control, 25(OH)D and 1,25(OH)<sub>2</sub>D levels were only minimally correlated ( $r^2$  0.158,  $P < 0.001$ ) and, also, do not vary by season. In contrast to 25(OH)D, there were no other life-style predictors for 1,25(OH)<sub>2</sub>D except menopausal hormone therapy use. Diabetes was significantly associated with lower levels of 25(OH)D and 1,25(OH)<sub>2</sub>D in blood: after adjustment for confounding factors, including sex, geographical location, educational level, smoking history, BMI, PA, total dietary energy, vitamin D and Ca intake and blood vitamin D (25(OH)D or 1,25(OH)<sub>2</sub>D (as appropriate)). Caucasians who had 25(OH)D  $\geq 80$  nmol/l 25(OH)D were half as likely to

have diabetes (OR 0.5 (95% CI 0.3, 0.9)) compared with those who had 25(OH)D  $< 37$  nmol/l (trend test:  $P = 0.05$ ). Those in the highest quartile of 1,25(OH)<sub>2</sub>D ( $\geq 103$  pmol/l) were a third as likely to have diabetes (OR 0.3 (95% CI 0.1, 0.7)) than those in the lowest quartile ( $< 72$  pmol/l; trend test:  $P = 0.02$ ). In contrast, there were no significant associations between 25(OH)D or 1,25(OH)<sub>2</sub>D and CHD or hypertension risk once adjustment was made for confounding (BMI was the major confounder) (Table 2). There were no sex differences with any of these chronic conditions and 25(OH)D or 1,25(OH)<sub>2</sub>D ( $P_{\text{interaction}} > 0.05$ ).

## Discussion

The present findings for 25(OH)D and diabetes support the results of earlier clinical and animal studies<sup>(5-7)</sup>, and are

**Table 1.** Distribution of demographic, lifestyle habits and dietary intake by low serum 25-hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D), diabetes, hypertension and CHD status in Caucasian healthy middle-aged men and women living across the USA

	Total (n 2465)	25(OH)D < 37 nmol/l (n 269)	1,25(OH) <sub>2</sub> D < 72 pmol/l (n 352)	Diabetes (n 170)	Hypertension (n 724)	CHD (n 248)
Categorical variables† (%)						
Demographics						
Sex: female	47	46	71	33**	55	23**
Education: above high school	93	92	94	88**	91*	94
Chronic conditions and lifestyle habits						
Diabetes	7	11*	9*		12**	16**
CHD	10	12	10	24**	19**	
Hypertension	30	36*	33	50**		54**
Lifestyle habits						
MHT use (current)‡	54	45*	41**	43	52	45
MHT use (ever)§	71	63	66	57*	69	59*
Smoking (pack years) > 40	25	25	22	37**	29*	31*
Vigorous exercise (current) ( $\geq 3$ h/week)	40	28**	36	35	36**	43
Vitamin supplement intake						
Multi-vitamins (recent)	65	48**	70	53**	62	63
Continuous variables						
Age (years)						
Mean	63	63	63	65**	64**	66**
SD	5	5	4	5	5	5
Anthropometry						
BMI (current; kg/m <sup>2</sup> )						
Mean	27	29**	28	30**	29**	28**
SD	5	5	6	6	5	5
Nutrients from diet and supplements						
Energy from diet (kJ/d)						
Mean	8680	8575	8115	8826	8717	9044
SD	3587	3557	3189	4436	3821	3553
Total fat from diet (g/d)						
Mean	69	67	64	74*	69	70
SD	35	32	31	40	36	35
Ca from diet and supplements (mg/d)						
Mean	1261	1022**	1353	1237	1197**	1182*
SD	631	530	681	823	609	550
Vitamin E from diet and supplements (mg/d)						
Mean	182	123**	210	159	183	209
SD	254	222	272	240	262	271
Vitamin D from diet and supplements ( $\mu$ g/d)						
Mean	12	7**	12	11	11*	11
SD	9	7	8	9	8	8

MHT, menopausal hormone therapy.

Values were significantly different: \* $P < 0.01$ , \*\* $P < 0.001$ .

†  $\chi^2$   $P$  value testing for difference between the category *v.* the converse.

‡  $n$  616 women.

§  $n$  813 women.


||  $P$  value for significance of Pearson correlation coefficient.

consistent with other large epidemiological cross-sectional studies that have investigated the relationship between serum 25(OH)D levels and diabetes<sup>(5,15)</sup>. Two recent prospective investigations also support this hypothesis: in the first study, which was conducted among 524 women and men in the UK, baseline 25(OH)D levels were inversely associated with glycaemia and insulin resistance after a 10-year follow-up<sup>(16)</sup>. In the second study, which used data from two nested case-control studies in Finland, baseline 25(OH)D levels were significantly inversely associated with type 2 diabetes risk after a 22-year follow-up, but only in men<sup>(17)</sup>. None of these studies investigated associations with 1,25(OH)<sub>2</sub>D nor did they investigate CHD or the risk of hypertension.

Several small clinical intervention studies also support that vitamin D, or its active metabolite 1,25(OH)<sub>2</sub>D, improves insulin sensitivity, even in subjects with glucose metabolism parameters classified within normal ranges<sup>(5)</sup>. The mechanisms

proposed to explain this effect include potential relationships with improvements in lean mass, regulation of insulin release, altered insulin receptor expression and specific effects on insulin action. These actions may be mediated by systemic or local production of 1,25(OH)<sub>2</sub>D or by suppression of the parathyroid hormone, which may function to negatively affect insulin sensitivity<sup>(5-7,15-19)</sup>. However, since the present study is cross-sectional, we cannot rule out that being diabetic could modify the regulation of renal synthesis of 1,25(OH)<sub>2</sub>D, which would be reflected in the concentration of this hormone in the blood.

Vitamin D status is of interest with respect to diabetes because of its potential as a target for intervention. Maintaining adequate vitamin D status has proven to be challenging, as sunlight is the only substantial natural source of vitamin D for humans; given the low intensity of UV light in the winter and many people's indoor lifestyles, vitamin D



**Fig. 1.** (a) Distribution of 25-hydroxyvitamin D (25(OH)D) (nmol/l) levels by month of blood draw for diabetic (■-■) and non-diabetic (◆-◆) healthy middle-aged Caucasian US men and women. (b) Distribution of 1,25(OH)<sub>2</sub>D (pmol/l) levels by month of blood draw for diabetic (■-■) and non-diabetic (◆-◆) healthy middle-aged Caucasian US men and women.

**Table 2.** Association between dietary vitamin D and calcium intake and serum 25-hydroxyvitamin D (25(OH)D) (nmol/l) and 1,25-dihydroxyvitamin D (1,25(OH)<sub>2</sub>D) (pmol/l) and diabetes, hypertension and CHD prevalence in Caucasian men and women living across the USA

Serum/diet	n	Diabetes (n 170)				Hypertension (n 724)				CHD (n 248)			
		OR*	95% CI	OR†	95% CI	OR*	95% CI	OR†	95% CI	OR*	95% CI	OR†	95% CI
<b>25 (OH)D‡ (nmol/l)</b>													
< 37	269	1.0		1.0		1.0		1.0		1.0		1.0	
≥ 37–50	442	0.7	0.4, 1.2	0.7	0.4, 1.2	0.8	0.6, 1.1	0.9	0.6, 1.2	0.7	0.4, 1.2	0.7	0.4, 1.1
≥ 50–80	1239	0.7	0.4, 1.0	0.7	0.4, 1.1	0.7	0.6, 1.0	0.9	0.7, 1.2	1.0	0.6, 1.4	1.1	0.7, 1.7
≥ 80	514	0.3	0.2, 0.6	0.5	0.3, 0.9	0.6	0.5, 0.9	1.0	0.7, 1.4	0.5	0.3, 0.9	0.7	0.4, 1.3
P trend			<0.001		0.02		0.004		NS		NS		NS
<b>Ca from diet and supplements (mg/d) (quartiles)</b>													
< 791	595	1.0		1.0		1.0		1.0		1.0		1.0	
≥ 791 to <1137	618	0.8	0.5, 1.2	0.9	0.6, 1.5	0.8	0.7, 1.1	0.8	0.6, 1.1	0.8	0.6, 1.2	0.7	0.5, 1.1
≥ 1137 to <1597	621	0.7	0.4, 1.0	0.8	0.4, 1.3	0.8	0.7, 1.1	0.8	0.6, 1.1	0.9	0.6, 1.3	0.9	0.5, 1.3
≥ 1597	631	0.7	0.5, 1.1	0.8	0.4, 1.5	0.7	0.5, 0.9	0.7	0.5, 1.0	0.7	0.5, 1.0	0.7	0.4, 1.1
P trend			NS		NS		0.004		0.05		0.06		NS
<b>Vitamin D from diet and supplements (µg/d) (quartiles)</b>													
< 4.5	599	1.0		1.0		1.0		1.0		1.0		1.0	
≥ 4.5 to <11	624	1.2	0.8, 1.9	1.2	0.7, 1.8	0.9	0.7, 1.1	1.0	0.7, 1.3	1.3	0.9, 1.8	1.2	0.8, 1.8
≥ 11 to <16	629	0.9	0.6, 1.5	0.9	0.5, 1.5	0.9	0.7, 1.1	1.1	0.8, 1.4	1.1	0.8, 1.6	1.5	1.0, 2.3
≥ 16	613	0.8	0.5, 1.2	0.8	0.4, 1.4	0.8	0.6, 1.1	1.1	0.8, 1.5	0.9	0.6, 1.4	1.2	0.7, 2.0
P trend			NS		NS		NS		NS		NS		NS
<b>1,25(OH)<sub>2</sub>D (pmol/l)</b>													
< 72	352	1.0		1.0		1.0		1.0		1.0		1.0	
≥ 72–86	347	0.7	0.4, 1.2	0.8	0.4, 1.5	1.0	0.7, 1.4	1.1	0.8, 1.5	0.6	0.3, 1.0	0.5	0.3, 1.0
≥ 86–103	339	0.6	0.3, 1.1	0.8	0.4, 1.5	0.9	0.6, 1.2	1.0	0.7, 1.4	0.7	0.4, 1.2	0.9	0.5, 1.5
≥ 103	331	0.2	0.1, 0.5	0.3	0.1, 0.7	0.7	0.5, 1.0	0.8	0.6, 1.2	0.7	0.4, 1.2	0.9	0.5, 1.7
P trend			<0.001		0.02		0.03		NS		NS		NS

\* Unadjusted for confounders and covariates.

† Adjusted for 1,25(OH)<sub>2</sub>D, study centre, different case-control study vitamin D analysis, date of blood draw, pack years of smoking, educational level, BMI, physical activity, sex, total dietary energy, dietary vitamin D and Ca plus supplements where appropriate.

‡ Missing data 25(OH)D (n 1).

§ Adjusted for 25(OH)D level, study centre, different case-control study vitamin D analysis, date of blood draw, pack years of smoking, educational level, BMI, physical activity, sex, total dietary energy, dietary vitamin D and Ca plus supplements where appropriate.

supplied through sun exposure is often inadequate to avoid deficiency.

In contrast to our findings, others, but not all, have reported associations between low levels of vitamin D in the blood and hypertension<sup>(4)</sup>; in summary, eighteen out of twenty-six cross-sectional studies (n 22–12 644) and of the two prospective studies, only one was positive<sup>(2,5)</sup>. As increased BMI is related to both hypertension and low vitamin D levels, it is important to consider it as a confounder in these studies. Only half of the positive observational studies adjusted for BMI; it should be noted that in the present data, a significant association with 25(OH)D or 1,25(OH)<sub>2</sub>D concentrations disappeared once BMI was added to the model. Similarly, the results from small, randomised, control trials have been variable with less than half positive<sup>(5)</sup>. Three of the large observational studies in the USA, UK and Germany reported significant associations between 25(OH)D and risk of hypertension after adjustment for diabetes prevalence<sup>(2,15,18)</sup>. One postulated mechanism for vitamin D-mediated reduction of hypertension involves reno-protective effects, i.e. increased activation of the renin-angiotensin-aldosterone system, which is the main regulator of electrolyte and volume homeostasis that contributes to the development of arterial hypertension<sup>(3,4)</sup>.

In contrast to our findings, some previous epidemiological studies have found a negative association between serum vitamin D and heart disease<sup>(3)</sup>, with ten out of twelve

observational studies (n 238–4839) of vascular disease (including two peripheral artery disease, five CVD) and five myocardial infarction) and six out of seven observational studies of heart failure (n 25–3299) showing a negative association between lower 25(OH)D levels and disease. Of these studies, only seven out of twelve adjusted for hypertension and diabetes, but none of these reported all three conditions separately in the same study<sup>(2,3)</sup>. It is thought that vitamin D plays a role in maintaining cardiovascular homeostasis both through direct action of 1,25(OH)<sub>2</sub>D on cardiomyocytes and indirect actions on circulating parathyroid hormone and Ca levels. The lack of association with CHD seen in these data could have been because of the low repeatability of the self-reported nature of this outcome variable and its associated variability compared with that of hypertension or diabetes.

The strengths of the present investigation are its large sample size, relatively low deficiency levels and the fact that the vitamin D analyses were all performed by the same assay method. Moreover, the present analysis is unique in reporting, in a large cohort study, the association between diabetes and blood levels of 1,25(OH)<sub>2</sub>D; to our knowledge, only associations of 1,25(OH)<sub>2</sub>D with hypertension<sup>(4)</sup>, CHD<sup>(5)</sup> and BMI<sup>(20)</sup> have been reported in large epidemiological groups. Important limitations of the present study include its cross-sectional design and reliance upon self-report of diabetes, hypertension and CHD status; however,



the measures of hypertension and diabetes had high reliability on follow-up. We had only one measure of adiposity (BMI), not total body fat, which is often thought to be more accurate; however, a recent validation study of BMI and dual-emission X-ray absorptiometry has reported very favourable correlations with adiposity<sup>(21)</sup>. We used only education as a marker for social class; however, this has been well accepted as the best marker for social class on an epidemiological level<sup>(22–24)</sup>. In particular, we cannot rule out the possibility that changes in sun exposure and/or diet as a consequence of having diabetes may have led to our findings; however, the associations reported here warrant investigation in large prospective studies. In summary, these data outlining the positive association between vitamin D blood markers and diabetes indicated the need for more investigation both at the biochemical and epidemiological levels.

### Acknowledgements

This research was supported in part by the Intramural Research Program of the National Cancer Institute (NCI), the National Institutes of Health (NIH). In addition, this research was supported by US Public Health Service contracts from NCI, NIH, the Department of Health and Human Services. All authors reviewed the final manuscript before submission, and none has a conflict of interest with regard to this work. K. E. B. was primary author in analysing the data and preparing the manuscript and coordinating the co-authors; R. Z. S.-S., D. M. F., J. A., U. P., C. M., R. G. Z. and M. P. P. were the primary investigators in the initial nested case–control studies used for this analysis and W.-Y. H. and M. P. P. are the overall co-ordinators of Prostate, Lung, Colorectal and Ovarian Screening Trial data, D. R. F. and R. S. M. and B. W. H. were involved in the vitamin D analysis aspects of the study; K. E. B., L. K. and B. I. G. were involved in the data analysis, and although K. E. B., M. T. and B. I. G. prepared the manuscript, all co-authors read and contributed to the final version, especially D. R. F. and R. S. M. read the vitamin D metabolism aspects.

### References

- Lips P (2006) Vitamin D physiology. *Prog Biophys Mol Biol* **92**, 4–8.
- Kendrick J, Targher G, Smits G, *et al.* (2009) 25-Hydroxy-vitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. *Atherosclerosis* **205**, 255–260.
- Nemerovski CW, Dorsch MP, Simpson RU, *et al.* (2009) Vitamin D and cardiovascular disease. *Pharmacotherapy* **29**, 691–708.
- Pilz S, Tomaschitz A, Ritz E, *et al.* (2009) Vitamin D status and arterial hypertension: a systematic review. *Nat Rev Cardiol* **6**, 621–630.
- Pittas AG, Lau J, Hu FB, *et al.* (2007) The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *J Clin Endocrinol Metab* **92**, 2017–2029.
- Christakos S, Friedlander EJ, Frandsen BR, *et al.* (1979) Studies on the mode of action of calciferol. XIII. Development of a radioimmunoassay for vitamin D-dependent chick intestinal calcium-binding protein and tissue distribution. *Endocrinology* **104**, 1495–1503.
- Norman AW, Frankel JB, Heldt AM, *et al.* (1980) Vitamin D deficiency inhibits pancreatic secretion of insulin. *Science* **209**, 823–825.
- Hayes RB, Reding D, Kopp W, *et al.* (2000) Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. *Control Clin Trials* **21**, 349S–355S.
- Brock K, Huang WY, Fraser DR, *et al.* (2010) Low vitamin D status is associated with physical inactivity, obesity and low vitamin D intake in a large US sample of healthy middle-aged men and women. *J Steroid Biochem Mol Biol* **121**, 462–466.
- Subar AF, Midthune D, Kulkdorff M, *et al.* (2000) Evaluation of alternative approaches to assign nutrient values to food groups in food frequency questionnaires. *Am J Epidemiol* **152**, 279–286.
- Tippett KS & Cypel YS (1997) *Design and Operation: The Continuing Survey of Food Intakes by Individuals and Diet and Health Knowledge Survey, 1994–96. Continuing Survey of Food Intakes by Individuals, Nationwide Food Surveys*. Washington, DC: US Department of Agriculture, Agricultural Research Service.
- Wagner D, Hanwell HE & Vieth R (2009) An evaluation of automated methods for measurement of serum 25-hydroxy-vitamin D. *Clin Biochem* **42**, 1549–1556.
- Hollis BW (1997) Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. *Methods Enzymol* **282**, 174–186.
- Breslow NE & Day NE (1980) Statistical methods in cancer research. Volume I – the analysis of case-control studies. *IARC Sci Publ* **32**, 5–338.
- Hyppönen E & Power C (2006) Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. *Diabetes Care* **29**, 2244–2246.
- Forouhi NG, Luan J, Cooper A, *et al.* (2008) Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. *Diabetes* **57**, 2619–2625.
- Knekt P, Laaksonen M, Mattila C, *et al.* (2008) Serum vitamin D and subsequent occurrence of type 2 diabetes. *Epidemiology* **19**, 666–671.
- Hintzpetter B, Mensink GB, Thierfelder W, *et al.* (2008) Vitamin D status and health correlates among German adults. *Eur J Clin Nutr* **62**, 1079–1089.
- Teegarden D & Donkin SS (2009) Vitamin D: emerging new roles in insulin sensitivity. *Nutr Res Rev* **22**, 82–92.
- Konradsen SAH, Lindberg F, Hexeberg S, *et al.* (2008) Serum 1,25-dihydroxy vitamin D is inversely associated with body mass index. *Eur J Nutr* **47**, 87–91.
- Flegal KM, Shepherd JA, Looker AC, *et al.* (2009) Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. *Am J Clin Nutr* **89**, 500–508.
- Kant AK & Graubard BI (2007) Ethnicity is an independent correlate of biomarkers of micronutrient intake and status in American adults. *J Nutr* **137**, 2456–2463.
- Winkleby MA, Jatulis DE, Frank E, *et al.* (1992) Socio-economic status and health: how education, income, and occupation contribute to risk factors for cardiovascular disease. *Am J Public Health* **82**, 816–820.
- Liberatos P, Link BG & Kelsey JL (1988) The measurement of social class in epidemiology. *Epidemiol Rev* **10**, 87–121.